ArticleBMC cancer2020
Smoking cessation and survival among people diagnosed with non-metastatic cancer.
Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- Lifestyle factors and all-cause mortality in long-term cancer survivors: a population-based prospective cohort study.European journal of epidemiology · 2026Article
- Smoking Cessation and Mortality Risk in Cancer Survivorship: Real-World Data From a National Cancer Institute-Designated Cancer Center.Journal of the National Comprehensive Cancer Network : JNCCN · 2025Observational
- Tobacco Assessment in Actively Accruing National Cancer Institute Clinical Trials Network Trials.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025Article
- Smoking Cessation Practices in Australian Oncology Settings: A Cross-Sectional Study of Who, How, and When.Asia-Pacific journal of clinical oncology · 2025Article
- Smoking cessation counselling patterns in cancer patients - survey of Lebanese physicians.Ecancermedicalscience · 2024Article
- Tobacco use and cancer-related symptom burden: Analysis of the US Population Assessment of Tobacco and Health Study.Cancer · 2023Article
- Effective Timing of Introducing an Inpatient Smoking Cessation Program to Cancer Patients.Yonsei medical journal · 2023Article
- Treating Smoking in Cancer Patients: An Essential Component of Cancer Care-The New National Cancer Institute Tobacco Control Monograph.JCO oncology practice · 2022Article
- Building staff capability, opportunity, and motivation to provide smoking cessation to people with cancer in Australian cancer treatment centres: development of an implementation intervention framework for the Care to Quit cluster randomised controlled trial.Health services & outcomes research methodology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to estimate the effects of smoking cessation on survival among people diagnosed with cancer.
methodsWe used data from a Comprehensive Community Cancer Program that is part of a large urban safety-net hospital system. Eligible patients were diagnosed with primary invasive solid tumors between 2013 and 2015, and were current smokers at time of diagnosis. Our exposure of interest was initiation of smoking cessation within 6 months of cancer diagnosis. We estimated inverse probability weighted restricted mean survival time (RMST) differences and risk ratio (RR) for all cause 3-year mortality.
resultsOur study population comprised 369 patients, of whom 42% were aged < 55 years, 59% were male, 44% were racial/ethnic minorities, and 59% were uninsured. The 3-year RMST was 1.8 (95% CL: - 1.5, 5.1) months longer for individuals who initiated smoking cessation within 6 months of cancer diagnosis. The point estimate for risk of 3-year mortality was lower for initiation of smoking cessation within 6 months of diagnosis compared with no initiation within 6 months (RR = 0.72, 95% CL: 0.37, 1.4).
conclusionsOur point estimates suggest longer 3-year survival, but the results are compatible with 1.5 month shorter or 5.1 longer 3-year overall survival after smoking cessation within 6 months of cancer diagnosis. Future studies with larger sample sizes that test the comparative effectiveness of different smoking cessation strategies are needed for more detailed evidence to inform decision-making about the effect of smoking cessation on survival among cancer patients. IMPLICATIONS FOR CANCER SURVIVORS: The benefits of smoking cessation after cancer diagnosis may include longer survival, but the magnitude of benefit is unclear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.